Merck & Co., Inc. is 153.2x more valuable than Trevi Therapeutics, Inc. by market capitalization ($298.26 B vs $1.95 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | TRVI | MRK |
|---|---|---|
| Market cap | $1.95 B | $298.26 B |
| US-listed rank | #2125 | #45 |
| Revenue (latest FY) | - | $65.01B |
| Net income (latest FY) | -$42.76M | $18.25B |
| Net margin | - | 28.1% |
| P/E (trailing FY) | - | 16.3 |
| SEC filings | 524 | 996 |
Merck & Co., Inc. is 153.2x more valuable than Trevi Therapeutics, Inc. by market capitalization ($298.26 B vs $1.95 B).
Full pages: Trevi Therapeutics, Inc. and Merck & Co., Inc., or browse the full rankings.